• Lung surfactants/mucolytics

Infasurf Generic Name & Formulations

General Description

Calfactant (as phospholipids 35mg/mL and 0.65mg proteins/mL); susp for intratracheal administration; preservative-free.

Pharmacological Class

Lung surfactant.

How Supplied

Single-use vials (6mL)—1


Infasurf Indications


Prevention and treatment of respiratory distress syndrome (RDS) in premature infants.

Infasurf Dosage and Administration


Not applicable.


See literature. Give by intratracheal administration through an endotracheal tube. 3mL/kg birth weight per dose (as 2 aliquots of 1.5mL/kg each) every 12 hours for 3 doses.

Infasurf Contraindications

Not Applicable

Infasurf Boxed Warnings

Not Applicable

Infasurf Warnings/Precautions


Interrupt dosing if reflux of product into endotracheal tube, cyanosis, bradycardia, airway obstruction, hypoventilation, or endotracheal tube dislodgement occurs; treat; resume after stabilization. Monitor respiratory status and clinical condition frequently and carefully.

Infasurf Pharmacokinetics

See Literature

Infasurf Interactions

Not Applicable

Infasurf Adverse Reactions

Adverse Reactions

Cyanosis, airway obstruction, bradycardia, reflux of surfactant into endotracheal tube, requirement for mechanical ventilation, reintubation, others.

Infasurf Clinical Trials

See Literature

Infasurf Note

Not Applicable

Infasurf Patient Counseling

See Literature